



Progressive Encephalomyelitis with Rigidity and Myoclonus Associated With Anti-GlyR Antibodies and Hodgkin's Lymphoma: A Case Report

Linda Borellini^{1,2*}, Silvia Lanfranconi¹, Sara Bonato^{1,2}, Ilaria Trezzi^{1,2}, Giulia Franco^{1,2}, Lorella Torretta³, Nereo Bresolin^{1,2} and Alessio Barnaba Di Fonzo^{1,2}

¹Neurology Department, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milan, Italy, ²Dino Ferrari Center, University of Milan, Milan, Italy, ³Aferesi Terapeutica, Centro Trasfusionale, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

OPEN ACCESS

Edited by:

Zsolt Illes,
University of Southern
Denmark, Denmark

Reviewed by:

Daniel Kondziella,
Rigshospitalet, Denmark
Helle Hvilsted Nielsen,
Odense University
Hospital, Denmark
Romana Höftberger,
Medical University of
Vienna, Austria

*Correspondence:

Linda Borellini
linda.borellini@gmail.com

Specialty section:

This article was submitted
to Multiple Sclerosis and
Neuroimmunology,
a section of the journal
Frontiers in Neurology

Received: 10 May 2017

Accepted: 25 July 2017

Published: 10 August 2017

Citation:

Borellini L, Lanfranconi S, Bonato S,
Trezzi I, Franco G, Torretta L,
Bresolin N and Di Fonzo AB (2017)
Progressive Encephalomyelitis with
Rigidity and Myoclonus Associated
With Anti-GlyR Antibodies and
Hodgkin's Lymphoma: A Case Report.
Front. Neurol. 8:401.
doi: 10.3389/fneur.2017.00401

Introduction: A 60-year-old man presented with a 6-month history of low back pain and progressive rigidity of the trunk and lower limbs, followed by pruritus, dysphonia, hyperhydrosis, and urinary retention. Brain and spinal imaging were normal. EMG showed involuntary motor unit hyperactivity. Onconeural, antiglutamic acid decarboxylase (anti-GAD), voltage-gated potassium channel, and dipeptidyl peptidase-like protein 6 (DPPX) autoantibodies were negative. CSF was negative. Symptoms were partially responsive to baclofen, gabapentin, and clonazepam, but he eventually developed severe dysphagia. Antiglycine receptor (anti-GlyR) antibodies turned out positive on both serum and CSF. A plasmapheresis cycle was completed with good clinical response. A PET scan highlighted an isolated metabolically active axillary lymphnode that turned out to be a classic type Hodgkin lymphoma (HL), in the absence of bone marrow infiltration nor B symptoms. Polychemotherapy with ABVD protocol was completed with good clinical response and at 1-year follow-up the neurological examination is normal.

Background: Progressive encephalomyelitis with rigidity and myoclonus (PERM) is a rare and severe neurological syndrome characterized by muscular rigidity and spasms as well as brain stem and autonomic dysfunction. It can be associated with anti-GAD, GlyR, and DPPX antibodies. All of these autoantibodies may be variably associated with malignant tumors and their response to immunotherapy, as well as to tumor removal, is not easily predictable.

Conclusion: Progressive encephalomyelitis with rigidity and myoclonus has already been described in association with HL, but this is the first case report of a HL manifesting as anti-GlyR antibodies related PERM. Our report highlights the importance of malignancy screening in autoimmune syndromes of suspected paraneoplastic origin.

Keywords: progressive encephalomyelitis with rigidity and myoclonus, glycine receptor antibodies, paraneoplastic syndromes, stiff person syndrome, Hodgkin's lymphoma

INTRODUCTION

A 60-year-old previously healthy man was referred to our hospital for subacute onset of severe and progressive gait disturbance associated with painful muscular spasms of the trunk and lower limbs. Symptoms appeared 5 months before with lumbar and left leg pain, followed by progressive gait difficulty especially in climbing stairs. At that time a first neurological examination was unremarkable except for positive Lasègue sign on the right side; 75 mg of oral prednisone was prescribed, with a partial relief of symptoms. Three months after symptoms, onset spontaneous and stimulus sensitive muscular spasms appeared, and an EMG confirmed involuntary continuous motor unit activity of all examined muscles. At that time a neurological examination disclosed bilateral achilles clonus associated with clubfoot and mallet fingers. Blood creatine kinases were slightly increased (up to 518 U/L), while autoantibodies [ANA, ENA, anti Hu-Yo-Ri-Amphiphysin-CV2-Ma2/Ta, and antiglutamic acid decarboxylase (anti-GAD)] were negative. Cerebrospinal fluid examination was normal. In order to rule out paraneoplastic syndromes, a total body CT scan was performed, showing two small axillary lymph nodes (defined as reactive) and a diffuse swelling and edema of left psoas, iliacus, pectineus, obturator externus, and quadratus lumborum, which was attributed to focal myositis. He was then treated with intravenous methylprednisolone followed by 1 mg/kg of oral prednisone. Despite treatment, he became wheelchair bound and was sent to rehabilitation, where he developed progressive dysphonia and diffuse pruritus on steroid tapering. For this reason he was admitted to our hospital.

Neurological examination showed marked dysphonia with rhynolalia and slight bilateral facial weakness. Ocular movements

were unaffected. Marked truncal and proximal lower limb rigidity, with incapacity to sit and stand unassisted, was noticed. Diffuse hyperreflexia with knee and ankle clonus was elicited. Cutaneous plantar reflex was flexor. He also had diffuse hyperhidrosis, constipation, and urinary retention. A therapy with oxibutinine and tamsulosine was prescribed, but he still required frequent autocatheterization. No muscular weakness, cerebellar signs, nor sensory defects were detected. However, he complained of severe dysesthesias and diffuse pruritus. After admission, he also developed severe dysphagia, requiring a feeding tube.

EMG was unremarkable, also in the paravertebral muscles. There was an increased cortical latency at both motor and sensory evoked potentials at the four limbs but brain and spinal MRI showed no abnormality except from the muscular swelling that had been mentioned at the first CT (**Figure 1A**). EEG was normal and there were no cognitive or psychiatric symptoms. A PET scan highlighted one of the two previously reported axillary lymph nodes as being enlarged and metabolically active (**Figures 1B–D**).

Symptoms markedly improved with clonazepam (up to 2.5 mg/day) and gabapentin (up to 1.200 mg/day). Steroid dosage increase up to 50 mg lead to a partial relief of sensory symptoms.

Blood tests were normal, including previously tested autoantibodies, voltage-gated potassium channel complex, and dipeptidyl peptidase-like protein 6 (DPPX) antibodies. GAD antibodies were still negative, as well as CSF examination, including protein level, IgG, and OGB. Finally, anti-GlyR (antiglycine receptor) antibodies were found to be positive on both serum and CSF samples, respectively. Meanwhile the patient started a plasmapheresis treatment, five cycles, 3,000 mL/cycle.

The metabolically active axillary lymph node was removed and its histological examination was consistent with a classic




FIGURE 1 | (A) T2 abdominal MRI revealing left psoas and bilateral paravertebral muscles edema and fatty substitution. **(B–D)** Total body CT-PET showing a hypermetabolic left axillary lymph node. We did not use copyrighted material from other sources (including the web).

type Hodgkin's lymphoma. Of note, there was no bone marrow infiltration, no elevation in β 2-microglobulin, nor lactate dehydrogenase in blood. Partial clinical improvement was observed 10 days after plasmapheresis. The patient was then able to stand unassisted and walk with minimal help. Dysphagia completely resolved few weeks after. He eventually was transferred at the Oncoematology Division to undergo polychemotherapy with ABVD protocol (doxorubicin, bleomycin, vinblastine, and dacarbazine). Over a 12-month follow-up period, a constant clinical improvement was observed despite tapering of immunosuppressive and symptomatic treatment. The patient was able to walk unassisted, to carry out usual activities including a full time job. He was still symptomatic for inconstant self-resolving stiffness in the morning (12 months mRS score was 1). A control PET scan was negative. The abdominal and pelvic muscles had a normal MRI appearance.

Written informed consent was obtained from the participant for the publication of this case report.

BACKGROUND

Progressive encephalomyelitis with rigidity and myoclonus (PERM) was first described 40 years ago by Whiteley et al. (1). It was also called stiff person plus syndrome, sharing some of its core clinical features and being sometimes associated with GAD autoimmunity. In 2008, anti-GlyR antibodies were detected in a typical PERM patient with hyperreflexia, rigidity, and brain stem signs (2), and in the following years, more cases were reported (3–8). An association with tumor has been reported in about 20% of cases (9). Recently, a novel antibody, namely anti-DPPX was reported to be associated with PERM with frequent gastrointestinal involvement (10–12). Another case report associates PERM to amphiphysin antibodies (13).

All of these autoantibodies have been related in variable frequency to malignant tumors and their response to immunotherapy, as well as tumor removal, is also not easily predictable (9–14).

DISCUSSION

To our knowledge, this is the first case report of a Hodgkin's lymphoma manifesting as glycine-receptor antibodies related PERM. In their prospective analysis of 45 GlyR antibodies positive patients, Carvajal-González et al. reported a case of PERM/myasthenia gravis plus syndrome in a 51-year-old male with a past history of successfully treated Hodgkin's lymphoma (14). Schmidt et al. describe a patient presenting with generalized pruritus, sleep disturbance and paroxysmal fear, followed by rapidly progressive

gait ataxia, generalized myoclonic jerks, severe dysautonomia, and respiratory failure who eventually developed a Hodgkin's lymphoma (15). There was no screening for antibodies against GlyR; however, the presence of status epilepticus and psychiatric features might also suggest an NMDAR encephalitis. In this regard, an overlap of the syndromes associated with both GlyR and NMDAR antibodies was described (5). The absence of seizures, psychiatric symptoms, and signs of hippocampal involvement in our patient did not prompt us to investigate NMDAR autoimmunity. McKeon et al. also report a case of stiff person syndrome with GlyR antibodies in a young man who 12 years later was diagnosed with Hodgkin's lymphoma. However, he never developed signs of brain stem involvement and the timing of the malignancy diagnosis makes this association questionable (16). Our patient did not complain systemic symptoms of malignancy. However, hyperhidrosis and itching, that are common in non-paraneoplastic PERM (14), could be interpreted as B symptoms as well. At CT scan, the lymphoma was overlooked, being described as a probably reactive lymph node. This highlights the importance of performing a more sensitive PET scan in patients with a strong suspect of a paraneoplastic syndrome.

Imaging showed atypical features in the abdominal and pelvic muscles. Such findings have not been described before and were partly misleading for diagnosis and treatment, since they suggested a focal myositis. The muscular edema resolving soon after symptomatic therapy rather than with immunotherapy suggests a possible association to hypercontraction rather than an inflammatory process. Interestingly, we noticed a similar CT and MRI muscle images in a young woman with anti-GAD-related stiff person syndrome with myopathic discharges at EMG, which eventually evolved into fibrous substitution.

In summary, we presented a case of PERM with GlyR antibodies as first manifestation of Hodgkin's lymphoma. A correct interpretation of symptoms and imaging investigations is of primary importance to rule out an underlying occult malignancy and speed up the appropriate treatment.

ETHICS STATEMENT

The study was exempt from this requirement. Non-applicable. The current study does not involve vulnerable populations.

AUTHOR CONTRIBUTIONS

LB and SL: clinical assessment, acquisition of data, manuscript drafting. SB, IT, GF, and LT: clinical assessment, acquisition of data. NB: clinical assessment, critical revision of manuscript. AD: critical revision of manuscript.

REFERENCES

- Whiteley AM, Swash M, Urich H. Progressive encephalomyelitis with rigidity. *Brain* (1976) 99:27–42. doi:10.1093/brain/99.1.27
- Hutchinson M, Waters P, McHugh J, Gorman G, O'Riordan S, Connolly S, et al. Progressive encephalomyelitis, rigidity and myoclonus: a novel glycine receptor antibody. *Neurology* (2008) 71:1291–2. doi:10.1212/01.wnl.0000327606.50322.f0
- Clerinx K, Breban T, Schrooten M, Leite MI, Vincent A, Verschakelen J, et al. Progressive encephalomyelitis with rigidity and myoclonus: resolution after thymectomy. *Neurology* (2011) 76:303–4. doi:10.1212/WNL.0b013e318207b008
- Piotrowicz A, Thümen A, Leite MI, Vincent A, Moser A. A case of glycine-receptor antibody-associated encephalomyelitis with rigidity and myoclonus (PERM): clinical course, treatment and CSF findings. *J Neurol* (2011) 258:2268–70. doi:10.1007/s00415-011-6078-x

5. Turner MR, Irani SR, Leite MI, Nithi K, Vincent A, Ansorge O. Progressive encephalomyelitis with rigidity and myoclonus. *Neurology* (2011) 77:439–43. doi:10.1212/WNL.0b013e318227b176
6. Mas N, Saiz A, Leite M, Waters P, Baron M, Castaño D, et al. Antiglycine-receptor encephalomyelitis with rigidity. *J Neurol Neurosurg Psychiatr* (2011) 82:1399–401. doi:10.1136/jnnp.2010.229104
7. Iizuka T, Leite M, Lang B, Waters P, Urano Y, Miyakawa S, et al. Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. *J Neurol* (2012) 259:1566–73. doi:10.1007/s00415-011-6377-2
8. Stern WM, Howard R, Chalmers RM, Woodhall MR, Waters P, Vincent A, et al. Glycine receptor antibody mediated progressive encephalomyelitis with rigidity and myoclonus (PERM): a rare but treatable neurological syndrome. *Pract Neurol* (2014) 14:123–7. doi:10.1136/practneurol-2013-000511
9. Baizabal-Carvallo JF, Jankovic J. Stiff-person syndrome: insights into a complex autoimmune disorder. *J Neurol Neurosurg Psychiatry* (2015) 86:840–8. doi:10.1136/jnnp-2014-309201
10. Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. *Ann Neurol* (2013) 73:120–8. doi:10.1002/ana.23756
11. Balint B, Jarius S, Nagel S, Haberkorn U, Probst C, Blöcker IM, et al. Progressive encephalomyelitis with rigidity and myoclonus. A new variant with DPPX antibodies. *Neurology* (2014) 84:1521–8. doi:10.1212/WNL.0000000000000372
12. Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, et al. DPPX potassium channel antibody. Frequency, clinical accompaniments, and outcomes in 20 patients. *Neurology* (2014) 83:1797–803. doi:10.1212/WNL.0000000000000991
13. Ishii A, Hayashi A, Ohkoshi N, Matsuno S, Shoji S. Progressive encephalomyelitis with rigidity associated with anti-amphiphysin antibodies. *J Neurol Neurosurg Psychiatry* (2004) 75:661–2. doi:10.1136/jnnp.2003.010504
14. Carvajal-González A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. *Brain* (2014) 137:2178–92. doi:10.1093/brain/awu142
15. Schmidt C, Freilinger T, Lieb M, Rémi J, Klein M, Straube A, et al. Progressive encephalomyelitis with rigidity and myoclonus preceding otherwise asymptomatic Hodgkin's lymphoma. *J Neurol Sci* (2010) 291:118–20. doi:10.1016/j.jns.2009.12.025
16. McKeon A, Martinez-Hernandez E, Lancaster E, Matsumoto JY, Harvey RJ, McEvoy KM, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. *JAMA Neurol* (2013) 70(1):44–50. doi:10.1001/jamaneurol.2013.574

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Borellini, Lanfranconi, Bonato, Trezzi, Franco, Torretta, Bresolin and Di Fonzo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.